Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. [electronic resource]

By:

Apolo, Andrea B

Contributor(s):

Infante, Jeffrey R
Balmanoukian, Ani
Patel, Manish R
Wang, Ding
Kelly, Karen
Mega, Anthony E
Britten, Carolyn D
Ravaud, Alain
Mita, Alain C
Safran, Howard
Stinchcombe, Thomas E
Srdanov, Marko
Gelb, Arnold B
Schlichting, Michael
Chin, Kevin
Gulley, James L

Producer: 20170825Description: 2117-2124 p. digitalISSN:

1527-7755

Subject(s):

Aged
Antibodies, Monoclonal -- administration & dosage
Antibodies, Monoclonal, Humanized
Cohort Studies
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Treatment Outcome
Urologic Neoplasms -- drug therapy

Online resources:

Available from publisher's website

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 35

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

There are no comments on this title.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

APA

Apolo A. B., Infante J. R., Balmanoukian A., Patel M. R., Wang D., Kelly K., Mega A. E., Britten C. D., Ravaud A., Mita A. C., Safran H., Stinchcombe T. E., Srdanov M., Gelb A. B., Schlichting M., Chin K. & Gulley J. L. (20170825). Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Apolo Andrea B, Infante Jeffrey R, Balmanoukian Ani, Patel Manish R, Wang Ding, Kelly Karen, Mega Anthony E, Britten Carolyn D, Ravaud Alain, Mita Alain C, Safran Howard, Stinchcombe Thomas E, Srdanov Marko, Gelb Arnold B, Schlichting Michael, Chin Kevin and Gulley James L. 20170825. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Apolo A. B., Infante J. R., Balmanoukian A., Patel M. R., Wang D., Kelly K., Mega A. E., Britten C. D., Ravaud A., Mita A. C., Safran H., Stinchcombe T. E., Srdanov M., Gelb A. B., Schlichting M., Chin K. and Gulley J. L. (20170825). Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Apolo Andrea B, Infante Jeffrey R, Balmanoukian Ani, Patel Manish R, Wang Ding, Kelly Karen, Mega Anthony E, Britten Carolyn D, Ravaud Alain, Mita Alain C, Safran Howard, Stinchcombe Thomas E, Srdanov Marko, Gelb Arnold B, Schlichting Michael, Chin Kevin and Gulley James L. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20170825.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC